The U.S. Food and Drug Administration (FDA) declined to approve Swedish drugmaker Sobi’s therapy to treat uncontrolled gout, a common form of inflammatory arthritis.
In its complete response letter, the FDA requested additional data related to chemistry, manufacturing, controls, and contract manufacturing facilities.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.